INTRODUCTION {#S1}
============

A novel coronavirus designated as SARS-CoV-2 in February 2020 by World Health organization (WHO) was identified as main cause of SARS like pneumonia cases in Wuhan city in Hubei Province of China at the end of 2019. This been recently declared as Global Pandemic by WHO. There is a global emergency to identify potential drugs to treat the SARS-CoV-2. Currently, there is no specific treatment against the new virus. There is a urgency to identifying potential antiviral agents to combat the disease is urgently needed. An effective and quick approach is to test existing antiviral drugs against SARS-CoV-2. Spike protein recognize and bind host receptors like ACE-2 and whose conformational changes facilitates fusion of viral envelop and host membrane leading viral entry into host cells. Replication of viral RNA occurs through RNA polymerase activity by n unique mechanism. Targeting protease like Spike protein for viral entry and polymerase for replication of virus in host cell can bring effective treatment against novel SARS-CoV-2.

Coronavirus are enveloped with a positive RNA genome. Coronaviridae family of the order Nidovirales, having four genera (α, β, γ and δ). sThe SARS-CoV-2 seems be β genus and probable origin from bat and suspected to have an intermittent host. Structurally coronavirus contain spike (S) protein, envelope (E) protein, membrane (M) protein and nucleocapsid (N) protein. Viral entry through host receptor attachment promoted by spike protein leading to viral fusion to cell membrane of the host and leading to infection. Incubation period may range from 7 days to 21 days with flu like symptoms or sometimes go asymptomatic. Spike protein determines the viral entry and infection. Antiviral therapies targeting human immune system and direct coronavirus are the primary methods of treating the viral infection. Innate immunity of human immune system plays important role as primary defence mechanism against coronavirus infection and its replication. Interferon plays key role in controlling viral replication and immune presentation of viral antigens and to enhance immune responses. Viral entry and replication require human cell signal pathways, by blocking such signal pathways can bring anti-viral effect. Previously known coronavirus infections SARS and MERS causing virus used angiotensin converting enzyme 2 (ACE2) and DPP4 human receptors of human cells independently. Targeting RNA-dependent RNA polymerase (RdRP) of coronavirus is second line of treatment itself include preventing the synthesis of viral RNA through acting on the genetic material of the virus inhibiting virus replication. Activation of the viral spike protein (S) by host cell proteases is essential for viral host cell attachment and entry and the responsible enzymes are potential therapeutic targets. The cellular proteases like furin, cathepsin and receptors like C-type lectins are Ca++-dependent glycan-binding proteins (GBPs) a functional receptor-mediated endocytosis in Golgi bodies plays important role viral infection, replication and maturation as shown in ([Figure 1](#F1){ref-type="fig"}).

Different strategies for developing drugs and treatment against SARS-CoV-2 include viral protein inhibitors and human cell receptor inhibitors to be studied extensively. Some interferon inhibition like ribavirin and cyclophilin were studied to treat coronavirus pneumonia. Interferon inhibition alone cannot treat the SARS-CoV-2, multi target therapy to be considered as effective way of treating which includes inhibition of receptor proteases like furins, viral proteins like spike (S) and Nsp12, a coronavirus, is an RNA-dependent RNA polymerase (RdRp) protein vital enzyme for coronavirus replication/transcription complex, which can inhibit both viral host cell entry and replication. As designing of novel molecules at present is time consuming and no present therapies existing to treat SARS-CoV-2, we propose use of existing antiviral and other drugs to treat the coronavirus infection. High-throughput screening, bioinformatics and AI based tools and methods to screen existing drug database is the fastest approach to discover drug leads against SARS-CoV-2 for example anti-retro viral drugs like Lopinavir and Ritonavir.

After determining the efficacy, the drugs can be approved through proper hospital based clinical trials for clinical treatment of patients. Viral encoding proteins and human cell proteins aiding viral host cell entry and replication were analysed by bioinformatics tools like Molecular docking and Swiss Dock protocols by conducting homology modelling and ligand preparations. SARS-CoV-2 Viral papain like protease, main protease, spike and RNA-dependent RNApolymerase (RdRp) and human furin human ACE2 and type-II transmembrane serine protease proteins were extensively used for targeted drug discovery. Virtual screening of proposed protein targets was docked against anti-HIV and anti-Hepatitis drugs were selected as ligands from drug database including some natural phytochemicals known for antiviral properties. The present study predicts wide range of drug leads that may inhibit this study predicts a variety of compounds that may inhibit novel SARS-CoV-2 coronavirus. Validation of successful drug leads should be studies for complete efficacy using proper in-vitro and in-vivo methods further to continue clinical studies.

METHODS {#S2}
=======

Methods & materials {#S3}
-------------------

### Homology genome blast and genomes information {#S4}

Whole genome of SARS-CoV-2 was obtained from NBCO Nucleotide database with reference number NC_045512.2. The nucleotide sequences were aligned using BLASTn sequence aligner and similarity search analysis with SARS-CoV-2 viral genomes submitted at NCBI from different samples of infected Cluster. MN908947 (complete genome) NC_045512 (reference sequence), LC522350 (gene region coded for RdRp), LC523807 (coded for N), LC523808 (coded for N), LC523809 (coded for N), LC528232 complete, LC528233 complete, LC529905 complete, LR757995 complete, LR757996 complete, LR757997 complete, gapped, LR757998 complete, MN938384 complete, MN938385RdRP, MN938386 RdRP, MN938387 S, MN938388 S, MN938389 S, MN938390 S, MN970003 RdRP, MN970004 RdRP, MN975262 complete, MN975263 RdRP, MN975264 RdRP, MN975265RdRP \[[@R1]--[@R3]\].

### Open reading frame finder {#S5}

ORF finder searches for open reading frames (ORFs) in the DNA sequence you enter. The program returns the range of each ORF, along with its protein translation. Use ORF finder to search newly sequenced DNA for potential protein encoding segments, verify predicted protein using newly developed SMART BLAST or regular BLASTP \[[@R1],[@R4],[@R5]\].

After genome alignment, the whole genome was searched for ORF domains using SMART BLAST. Quality parameters like minimal ORF length 75 with standard genetic code having ATG and initiation codons been set.

### Alignment of nucleotide and amino acid sequence analysis {#S6}

Nucleotide sequence editing was conducted using WebDSV 2.0. Protein alignment was done using Clustalw and protein to DNA sequence comparison done using pairwise alignment EMBL EBI tools \[[@R6],[@R7]\]. The homology model prediction was carried out through searching in RCSB database included in Fold and Function Assignment System. Prediction Binding pockets was done online [dockingserver.com](http://dockingserver.com). 3D structure structures are aligned by Autodock and pymol structure alignment tools.

COMPUTATIONAL METHODS {#S7}
=====================

Docking calculations were carried out using Docking Server. Gasteiger partial charges were added to the ligand atoms. Non-polar hydrogen atoms were merged, and rotatable bonds were defined \[[@R8]--[@R10]\].

Docking calculations were carried out on selected ligands to SARS-CoV-2 main protease PDB ID 6LU7, Human furin PDB ID6HZD, PDB ID 3E9S papain like protease and PDB ID 6NUR Nsp12 of SARS virus. Essential hydrogen atoms, Kollman united atom type charges, and solvation parameters were added with the aid of Autodock tools \[[@R11]\]. Affinity (grid) maps of Å grid points and 0.375 Å spacing were generated using the Autogrid program \[[@R11]\]. Swiss protein modelling and Autodock tools are used for protein clean. Autodock parameter set- and distance-dependent dielectric functions were used in the calculation of the van der Waals and the electrostatic terms, respectively \[[@R11]--[@R13]\].

Docking simulations were performed using the Lamarckian genetic algorithm (LGA) and the Solis & Wets local search method \[[@R12]\]. Initial position, orientation and torsions of the ligand molecules were set randomly. All rotatable torsions were released during docking. Each docking experiment was derived from 100 different runs that were set to terminate after a maximum of 2500000 energy evaluations. The population size was set to 150. During the search, a translational step of 0.2 Å and quaternion and torsion steps of 5 were applied.

RESULTS {#S8}
=======

Homology genome blast and genomes information {#S9}
---------------------------------------------

Genetic ID MN908947 SARS-CoV-2 isolate Wuhan-Hu-1, complete genome after BLASTn similarity search had shown more similarity with many bat coronaviruses, some unknown virus and for some synthetic recombinant virus with genetic ID FJ211859.1 see [Figure 2](#F2){ref-type="fig"} and [Figure 3](#F3){ref-type="fig"} for whole genome and distance tree analysis. After whole genome alignment in WebDSV 2.0 tools, forward and reverse primers identified as shown in [Figure 4](#F4){ref-type="fig"} and [Figure 5](#F5){ref-type="fig"} both circular and linear alignments for 29903 bp.

Open reading frame finder {#S10}
-------------------------

SMART BLAST analysis shows more than 283 open reading frames shown in supplementary file orf finder-NCBI and in [Table 1](#T1){ref-type="table"}. ORF16, ORF5, ORF8 had shown most proteins coding for mono-ADP-ribosyltransferase PARP protein families, helicases, coronavirus family proteins NSP11 and NSP13, papain like viral protease, Pfam super family proteins of orthocoronaviridae, APA3 viroporin: Coronavirus accessory protein 3a, orf3a protein of coronaviridae. ORF120 coded for BAT SARS coronavirus HKU3, HKU3--2 and HKU3--9 mainly origin from Rhinolophus affinis an Intermediate horseshoe bat widely available in Asia. ORF238 codes for enzymes dimethylaniline monooxygenase. All positive strand ORF's coded for Bat SARS coronavirus related proteins.

Docking results {#S11}
---------------

Selected paritaprevir, entecavir, ergotamine tartrate, telaprevir, dihydroergotamine, simeprevir, ergotamine alkaloid, telmisartan, ritonavir tartrate, fgi 106, corosolic acid, chloroquine, darunavir, nelfinavir, glycyrrhizic acid, baicalin, ritonavir, quilajja saponin, lopinavir, amprenavir, fosamprenavir, quercetin, remdesivir, pemetrexed, raltitrexed, sofosbuvir were docked against proteins SARS-CoV-2 main protease PDB ID 6LU7, Human furinPDB ID6HZD, PDB ID 3E9S papain like protease and PDB ID 6NUR Nsp12 (RdRp) in selective manner as mentioned in ([Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}).

Paritaprevir, chloroquine and ritonavir had shown strong multi target inhibition like spike proteins, proteases and furin. Natural compounds like baicalin, corosolic acid had shown multi target inhibition properties against spike proteins, proteases and furin.

DISCUSSION {#S12}
==========

At present world is facing pandemic situation because of SARS-CoV-2 infection. There is an urgency to address this situation as no present treatment protocols are not been established. The only way to develop quick treatment protocols can be achieved by studying detailed case studies of SARS infections caused by influenza and non-influenza viruses and also studying existing antiviral drugs.

Computational and high throughput screening tools are the best aids to design and study the efficacy of existing antiviral drugs along with some anti-inflammatory drugs against SARS-CoV-2 targeted sites. Antiviral drugs like oseltamivir used against neuraminidase of SARS in last decade, favilavir an RNA-Dependent RNA polymerase (RdRp) inhibitor also showed effective against the SARS influenza virus. Recently Japan also proposed use of favipiravir and Avian flu drug to treat SARS-CoV-2 infection. Remdesivir a proposed drug to treat Ebola virus also been proposed to test against SARS-CoV-2. DNA and RNA inhibitors like sofosbuvir and anti-HIV drug compositions also been proposed at present to treat the present global pandemic caused by novel coronavirus. Most of the proposed drugs had shown either less efficacy or effective in some patients but not achieved complete success. In order to develop complete treatment protocol, one should understand the disease pathogenesis. As per case reports available study indicates respiratory outburst due to various inflammatory study indicates severe diarrhoea and respiratory outburst due to inflammatory factors causing death among novel coronavirus infected patients. As per our study we found CD4+ activation leading to TH1 and TH2 cytokines outburst in excessive leading to severe respiratory illness in patients affected by SARS-CoV-2. This virus has Orf zone indicating C lectin type binding receptors of host ([Figure 4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"} and [6](#F6){ref-type="fig"}) which may make this virus to escape MHC Class I antigen presentation leading to asymptomatic conditions in some patients. Interleukins like IL6, IL8 and IL2 along with TNFα might be main causative inflammatory leading respiratory failure. Based on available case study by \[[@R14]\] most of the patients admitted had shown difficulty in breathing, cough and fever with severe respiratory illness and pneumonia. In this study we propose use of multi target therapy which includes viral protein targets involving in host cell entry and replication and host cytokines. Viral proteins like spike, neuraminidase, main protease (3CLpro), papain like protease (PLpro) and RNA-Dependent RNA polymerase (RdRp) are the key viral protein targets \[[@R2]\]. Inhibition of spike (S) protein binding to ACE 2 will be key prophylactic drug discovery to control SARS-CoV-2.

CONCLUSION {#S13}
==========

The present used carried out using computational and high throughput screening tools in order to evaluate the whole Genome analysis of SARS-CoV-2 and identifying potential drugs to treat novel coronavirus influenza. Gene sequence was obtained from NCBI genome database \[[@R15],[@R3]\] and Molbiol and other BLAST analysis tools were used to analyse genome wide study. Similarity search analysis had shown possible close species relation with BAT SARS Corona virus particularly from Intermediate horseshoe bat (Rhinolophus affinis) and some Beta Coronaviridae family. The data also suggest some possible cross species interaction of Delta coronavirus families and species jump from bats to intermediate host which is unknown or from porcine origin. VISTA Tools for Comparative Genomics had shown some phylogenetic origin of SARS-CoV-2 by chimeric recombination between HKU2 alpha Coronaviridae which caused severe Swine diarrhoea syndrome caused by Bat droppings and HKU15 a delta corona virus causing swine respiratory syndrome ([Figure 7](#F7){ref-type="fig"}). Some genome wide analysis also matches with Recombination Clone of SARS Coronavirus with genetic ID FJ211859.1 which should be properly evaluated as future indication. Orf reading had shown more than main 238 Orf sites SARS coronavirus Orf3/3a ([Figure 6](#F6){ref-type="fig"}) which is a characteristic protein for SARS Coronavirus family. Some other proteins include NS3/E, small non-structural proteins, well conserved among Coronavirus strains and a small uncharacteristic protein SARS_NS6 with small amino acid sequence. Drugs selected from zinc database like remdesivir, paritaprevir, sofosbuvir, ritonavir, lopinavir, chloroquine derivatives like hydroxychloroquine including natural molecules like glycyrrhizin, corosolic acid and baicalin were used as ligands in docking studies against viral proteins like spike, main protease (3CLpro). Papain like protease (PLpro), RNA dependent RNA polymerase. Docking results had shown paritaprevir, ritonavir and chloroquine derivatives as best drug leads against spike and proteases of SARS-Co-V2. Natural drugs like glycyrrhizin, corosolic acid and baicalin also shown strong binding affinity against spike and protease proteins of novel corona virus. From existing clinical data, we also propose use of anti-inflammatory drugs in treating the SARS-CoV-2 disease progression. In this study we propose for clinical study by combined use of paritaprevir, entecavir, ritonavir, and hydroxychloroquine along with anti-inflammatory drugs and also use of niacinamide, vitamin C, zinc supplements for possible good clinical outcome. We also propose study plant protease inhibitors (PI's), glycoprotein-based antibodies and small molecules like Lysozyme hydrochloride, Oxamniquine and Nateglinide therapies.
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Multiple sequence alignment viewer of distance tree of genome of SARS-CoV-2 genetic ID MN908947.3.
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![Distance tree of SARS-CoV-2 viral genome genetic ID MN908947.3 by blastn suite.](nihms-1582187-f0005){#F3}
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![ProrVista tool analysis of ORF reads of SARS-CoV-2.](nihms-1582187-f0008){#F6}

![VISTA GENOME TOOL COMPRATIVE ANALYSIS-JQ065043.2--HKU2 swine corona virus, NC 009988.1 HKU15 SARS coronavirus from horseshoe bats (Rhinolophus) & MN908947.3 SARS-CoV-2.](nihms-1582187-f0009){#F7}

###### 

Open reading frames in whole genome of SARS-CoV-2.

  Label        Strand   Frame   Start   Stop    Length (nt \| aa)
  ------------ -------- ------- ------- ------- -------------------
  **ORF16**    \+       2       266     13483   13218 \| 4405
  **ORF5**     \+       1       13768   21555   7788 \| 2595
  **ORF42**    \+       2       21521   25384   3864 \| 1287
  **ORF50**    \+       2       28274   29533   1260 \| 419
  **ORF8**     \+       1       25393   26220   828 \| 275
  **ORF117**   \+       3       26499   27191   693 \| 230
  **ORF215**   −        2       1843    1391    453 \| 150
  **ORF278**   −        3       2712    2290    423 \| 140
  **ORF119**   \+       3       27894   28259   366 \| 121
  **ORF12**    \+       1       27394   27759   366 \| 121
  **ORF214**   −        2       2917    2561    357 \| 118
  **ORF220**   −        3       29151   28813   339 \| 112
  **ORF269**   −        3       6489    6187    303 \| 100
  **ORF120**   \+       3       28278   28577   300 \| 99
  **ORF180**   −        2       23494   23198   297 \| 98
  **ORF98**    \+       3       21918   22199   282 \| 93
  **ORF168**   −        2       29140   28862   279 \| 92
  **ORF234**   −        3       23349   23074   276 \| 91
  **ORF229**   −        3       25368   25099   270 \| 89
  **ORF161**   −        1       3263    3006    258 \| 85
  **ORF65**    \+       3       2958    3206    249 \| 82
  **ORF121**   \+       3       28710   28955   246 \| 81
  **ORF238**   −        3       20010   19765   246 \| 81
  **ORF217**   −        2       667     422     246 \| 81
  **ORF233**   −        3       23919   23680   240 \| 79
  **ORF193**   −        2       12355   12122   234 \| 77
  **ORF9**     \+       1       26245   26472   228 \| 75
  **ORF97**    \+       3       21639   21863   225 \| 74
  **ORF173**   −        2       25807   25586   222 \| 73
  **ORF56**    \+       3       888     1097    210 \| 69
  **ORF102**   \+       3       22884   23093   210 \| 69
  **ORF88**    \+       3       10191   10400   210 \| 69
  **ORF21**    \+       2       15461   15667   207 \| 68
  **ORF167**   −        2       29413   29207   207 \| 68
  **ORF140**   −        1       18185   17979   207 \| 68
  **ORF257**   −        3       11904   11701   204 \| 67
  **ORF171**   −        2       27007   26804   204 \| 67
  **ORF254**   −        3       12486   12283   204 \| 67
  **ORF181**   −        2       22111   21911   201 \| 66
  **ORF128**   −        1       26378   26181   198 \| 65
  **ORF132**   −        1       21038   20844   195 \| 64
  **ORF75**    \+       3       6156    6350    195 \| 64
  **ORF68**    \+       3       3912    4103    192 \| 63
  **ORF150**   −        1       13550   13359   192 \| 63
  **ORF225**   −        3       27225   27034   192 \| 63
  **ORF48**    \+       2       26684   26872   189 \| 62
  **ORF100**   \+       3       22539   22724   186 \| 61
  **ORF205**   −        2       6019    5834    186 \| 61
  **ORF232**   −        3       24111   23926   186 \| 61
  **ORF11**    \+       1       27202   27387   186 \| 61
  **ORF25**    \+       2       16616   16798   183 \| 60
  **ORF282**   −        3       315     133     183 \| 60
  **ORF260**   −        3       10995   10819   177 \| 58
  **ORF126**   −        1       29552   29376   177 \| 58
  **ORF164**   −        1       692     516     177 \| 58
  **ORF252**   −        3       13053   12880   174 \| 57
  **ORF253**   −        3       12765   12592   174 \| 57
  **ORF243**   −        3       18324   18151   174 \| 57
  **ORF147**   −        1       14486   14313   174 \| 57
  **ORF115**   \+       3       25524   25697   174 \| 57
  **ORF55**    \+       3       711     881     171 \| 56
  **ORF261**   −        3       10767   10597   171 \| 56
  **ORF74**    \+       3       5919    6089    171 \| 56
  **ORF78**    \+       3       7542    7709    168 \| 55
  **ORF250**   −        3       15159   14992   168 \| 55
  **ORF108**   \+       3       23874   24041   168 \| 55
  **ORF87**    \+       3       9951    10115   165 \| 54
  **ORF280**   −        3       1689    1528    162 \| 53
  **ORF196**   −        2       10384   10223   162 \| 53
  **ORF59**    \+       3       1578    1739    162 \| 53
  **ORF67**    \+       3       3594    3752    159 \| 52
  **ORF118**   \+       3       27729   27887   159 \| 52
  **ORF192**   −        2       13273   13115   159 \| 52
  **ORF231**   −        3       24561   24406   156 \| 51
  **ORF95**    \+       3       13311   13466   156 \| 51
  **ORF242**   −        3       18543   18388   156 \| 51
  **ORF36**    \+       2       19148   19303   156 \| 51
  **ORF178**   −        2       24178   24023   156 \| 51
  **ORF125**   −        1       29840   29685   156 \| 51
  **ORF207**   −        2       5641    5486    156 \| 51
  **ORF275**   −        3       3963    3811    153 \| 50
  **ORF265**   −        3       8949    8797    153 \| 50
  **ORF237**   −        3       21135   20983   153 \| 50
  **ORF272**   −        3       5022    4873    150 \| 49
  **ORF52**    \+       3       276     425     150 \| 49
  **ORF26**    \+       2       16973   17122   150 \| 49
  **ORF190**   −        2       14059   13910   150 \| 49
  **ORF40**    \+       2       20993   21142   150 \| 49
  **ORF157**   −        1       6404    6258    147 \| 48
  **ORF138**   −        1       19292   19146   147 \| 48
  **ORF256**   −        3       12078   11932   147 \| 48
  **ORF155**   −        1       10649   10503   147 \| 48
  **ORF135**   −        1       20150   20007   144 \| 47
  **ORF127**   −        1       28871   28728   144 \| 47
  **ORF146**   −        1       14651   14508   144 \| 47
  **ORF191**   −        2       13441   13298   144 \| 47
  **ORF70**    \+       3       4692    4835    144 \| 47
  **ORF136**   −        1       19856   19713   144 \| 47
  **ORF244**   −        3       17994   17851   144 \| 47
  **ORF186**   −        2       16939   16799   141 \| 46
  **ORF17**    \+       2       14288   14428   141 \| 46
  **ORF203**   −        2       7825    7688    138 \| 45
  **ORF112**   \+       3       24606   24743   138 \| 45
  **ORF174**   −        2       24988   24851   138 \| 45
  **ORF197**   −        2       10177   10040   138 \| 45
  **ORF104**   \+       3       23220   23357   138 \| 45
  **ORF189**   −        2       15703   15566   138 \| 45
  **ORF4**     \+       1       10951   11088   138 \| 45
  **ORF202**   −        2       8371    8237    135 \| 44
  **ORF273**   −        3       4458    4324    135 \| 44
  **ORF33**    \+       2       18392   18523   132 \| 43
  **ORF222**   −        3       27771   27640   132 \| 43
  **ORF76**    \+       3       7236    7367    132 \| 43
  **ORF156**   −        1       7538    7407    132 \| 43
  **ORF86**    \+       3       9201    9329    129 \| 42
  **ORF23**    \+       2       16151   16279   129 \| 42
  **ORF105**   \+       3       23385   23513   129 \| 42
  **ORF90**    \+       3       12318   12443   126 \| 41
  **ORF43**    \+       2       25457   25582   126 \| 41
  **ORF177**   −        2       24367   24242   126 \| 41
  **ORF133**   −        1       20576   20451   126 \| 41
  **ORF13**    \+       1       28066   28191   126 \| 41
  **ORF6**     \+       1       24688   24813   126 \| 41
  **ORF109**   \+       3       24045   24170   126 \| 41
  **ORF122**   \+       3       28962   29084   123 \| 40
  **ORF264**   −        3       9288    9166    123 \| 40
  **ORF148**   −        1       14027   13905   123 \| 40
  **ORF245**   −        3       17628   17506   123 \| 40
  **ORF14**    \+       1       29173   29295   123 \| 40
  **ORF216**   −        2       1021    899     123 \| 40
  **ORF83**    \+       3       8856    8975    120 \| 39
  **ORF114**   \+       3       25329   25448   120 \| 39
  **ORF221**   −        3       28413   28297   117 \| 38
  **ORF18**    \+       2       14636   14752   117 \| 38
  **ORF107**   \+       3       23640   23756   117 \| 38
  **ORF169**   −        2       28522   28406   117 \| 38
  **ORF34**    \+       2       18647   18763   117 \| 38
  **ORF279**   −        3       2046    1930    117 \| 38
  **ORF51**    \+       2       29558   29674   117 \| 38
  **ORF110**   \+       3       24213   24329   117 \| 38
  **ORF113**   \+       3       24762   24875   114 \| 37
  **ORF200**   −        2       8785    8672    114 \| 37
  **ORF71**    \+       3       5103    5216    114 \| 37
  **ORF208**   −        2       5011    4901    111 \| 36
  **ORF1**     \+       1       5803    5913    111 \| 36
  **ORF142**   −        1       17276   17166   111 \| 36
  **ORF266**   −        3       8754    8644    111 \| 36
  **ORF45**    \+       2       26060   26170   111 \| 36
  **ORF111**   \+       3       24330   24440   111 \| 36
  **ORF28**    \+       2       17606   17716   111 \| 36
  **ORF24**    \+       2       16493   16603   111 \| 36
  **ORF54**    \+       3       576     686     111 \| 36
  **ORF277**   −        3       2949    2842    108 \| 35
  **ORF153**   −        1       12083   11976   108 \| 35
  **ORF123**   \+       3       29160   29267   108 \| 35
  **ORF124**   \+       3       29343   29450   108 \| 35
  **ORF139**   −        1       18578   18471   108 \| 35
  **ORF159**   −        1       4298    4191    108 \| 35
  **ORF211**   −        2       3466    3359    108 \| 35
  **ORF210**   −        2       3685    3578    108 \| 35
  **ORF62**    \+       3       2208    2312    105 \| 34
  **ORF204**   −        2       7336    7232    105 \| 34
  **ORF81**    \+       3       7998    8102    105 \| 34
  **ORF267**   −        3       8148    8044    105 \| 34
  **ORF85**    \+       3       9090    9194    105 \| 34
  **ORF201**   −        2       8581    8477    105 \| 34
  **ORF92**    \+       3       12669   12773   105 \| 34
  **ORF184**   −        2       17377   17273   105 \| 34
  **ORF271**   −        3       5577    5473    105 \| 34
  **ORF106**   \+       3       23520   23624   105 \| 34
  **ORF31**    \+       2       18086   18187   102 \| 33
  **ORF53**    \+       3       432     533     102 \| 33
  **ORF281**   −        3       1110    1009    102 \| 33
  **ORF224**   −        3       27456   27355   102 \| 33
  **ORF61**    \+       3       1866    1967    102 \| 33
  **ORF63**    \+       3       2583    2684    102 \| 33
  **ORF57**    \+       3       1128    1229    102 \| 33
  **ORF255**   −        3       12255   12154   102 \| 33
  **ORF84**    \+       3       8982    9083    102 \| 33
  **ORF240**   −        3       18978   18877   102 \| 33
  **ORF219**   −        3       29511   29410   102 \| 33
  **ORF152**   −        1       13058   12957   102 \| 33
  **ORF154**   −        1       10856   10755   102 \| 33
  **ORF116**   \+       3       25968   26069   102 \| 33
  **ORF195**   −        2       11596   11498   99 \| 32
  **ORF283**   −        3       108     10      99 \| 32
  **ORF274**   −        3       4236    4138    99 \| 32
  **ORF235**   −        3       22599   22501   99 \| 32
  **ORF236**   −        3       21372   21274   99 \| 32
  **ORF199**   −        2       9493    9395    99 \| 32
  **ORF239**   −        3       19101   19003   99 \| 32
  **ORF268**   −        3       7419    7321    99 \| 32
  **ORF248**   −        3       15888   15790   99 \| 32
  **ORF263**   −        3       10371   10273   99 \| 32
  **ORF39**    \+       2       20165   20263   99 \| 32
  **ORF187**   −        2       16306   16208   99 \| 32
  **ORF158**   −        1       5546    5448    99 \| 32
  **ORF141**   −        1       17543   17445   99 \| 32
  **ORF46**    \+       2       26183   26281   99 \| 32
  **ORF10**    \+       1       26812   26910   99 \| 32
  **ORF131**   −        1       21551   21453   99 \| 32
  **ORF47**    \+       2       26456   26554   99 \| 32
  **ORF143**   −        1       16295   16200   96 \| 31
  **ORF213**   −        2       3190    3095    96 \| 31
  **ORF212**   −        2       3298    3203    96 \| 31
  **ORF276**   −        3       3450    3355    96 \| 31
  **ORF103**   \+       3       23106   23201   96 \| 31
  **ORF259**   −        3       11154   11059   96 \| 31
  **ORF179**   −        2       23632   23537   96 \| 31
  **ORF66**    \+       3       3207    3302    96 \| 31
  **ORF246**   −        3       17106   17011   96 \| 31
  **ORF194**   −        2       11842   11747   96 \| 31
  **ORF91**    \+       3       12480   12572   93 \| 30
  **ORF228**   −        3       25602   25510   93 \| 30
  **ORF72**    \+       3       5565    5657    93 \| 30
  **ORF44**    \+       2       25892   25984   93 \| 30
  **ORF77**    \+       3       7377    7469    93 \| 30
  **ORF188**   −        2       15991   15899   93 \| 30
  **ORF160**   −        1       3830    3738    93 \| 30
  **ORF7**     \+       1       25195   25287   93 \| 30
  **ORF163**   −        1       1904    1812    93 \| 30
  **ORF270**   −        3       6072    5980    93 \| 30
  **ORF19**    \+       2       14765   14857   93 \| 30
  **ORF206**   −        2       5779    5687    93 \| 30
  **ORF172**   −        2       26536   26447   90 \| 29
  **ORF249**   −        3       15696   15607   90 \| 29
  **ORF185**   −        2       17200   17111   90 \| 29
  **ORF80**    \+       3       7893    7982    90 \| 29
  **ORF251**   −        3       14367   14278   90 \| 29
  **ORF176**   −        2       24595   24506   90 \| 29
  **ORF101**   \+       3       22776   22865   90 \| 29
  **ORF129**   −        1       25454   25365   90 \| 29
  **ORF134**   −        1       20438   20349   90 \| 29
  **ORF227**   −        3       26127   26038   90 \| 29
  **ORF170**   −        2       28105   28016   90 \| 29
  **ORF175**   −        2       24811   24725   87 \| 28
  **ORF60**    \+       3       1770    1856    87 \| 28
  **ORF22**    \+       2       15812   15898   87 \| 28
  **ORF247**   −        3       16818   16732   87 \| 28
  **ORF183**   −        2       17854   17768   87 \| 28
  **ORF30**    \+       2       17966   18052   87 \| 28
  **ORF144**   −        1       15617   15531   87 \| 28
  **ORF73**    \+       3       5697    5783    87 \| 28
  **ORF35**    \+       2       18764   18847   84 \| 27
  **ORF2**     \+       1       8815    8898    84 \| 27
  **ORF32**    \+       2       18284   18367   84 \| 27
  **ORF41**    \+       2       21317   21400   84 \| 27
  **ORF58**    \+       3       1476    1559    84 \| 27
  **ORF258**   −        3       11577   11494   84 \| 27
  **ORF151**   −        1       13277   13194   84 \| 27
  **ORF165**   −        1       227     144     84 \| 27
  **ORF182**   −        2       18703   18620   84 \| 27
  **ORF94**    \+       3       13005   13088   84 \| 27
  **ORF166**   −        2       29500   29417   84 \| 27
  **ORF145**   −        1       15143   15060   84 \| 27
  **ORF130**   −        1       22352   22269   84 \| 27
  **ORF223**   −        3       27621   27538   84 \| 27
  **ORF137**   −        1       19700   19617   84 \| 27
  **ORF82**    \+       3       8745    8825    81 \| 26
  **ORF162**   −        1       2561    2481    81 \| 26
  **ORF27**    \+       2       17393   17473   81 \| 26
  **ORF29**    \+       2       17831   17911   81 \| 26
  **ORF149**   −        1       13631   13551   81 \| 26
  **ORF226**   −        3       26226   26146   81 \| 26
  **ORF262**   −        3       10509   10429   81 \| 26
  **ORF49**    \+       2       27875   27955   81 \| 26
  **ORF99**    \+       3       22314   22394   81 \| 26
  **ORF79**    \+       3       7758    7838    81 \| 26
  **ORF69**    \+       3       4350    4430    81 \| 26
  **ORF89**    \+       3       12126   12206   81 \| 26
  **ORF15**    \+       2       59      136     78 \| 25
  **ORF209**   −        2       4408    4331    78 \| 25
  **ORF20**    \+       2       14858   14935   78 \| 25
  **ORF3**     \+       1       9541    9618    78 \| 25
  **ORF198**   −        2       9964    9887    78 \| 25
  **ORF218**   −        2       310     233     78 \| 25
  **ORF37**    \+       2       19550   19627   78 \| 25
  **ORF38**    \+       2       19664   19741   78 \| 25
  **ORF230**   −        3       24966   24889   78 \| 25
  **ORF96**    \+       3       21117   21194   78 \| 25
  **ORF93**    \+       3       12864   12941   78 \| 25
  **ORF64**    \+       3       2793    2870    78 \| 25
  **ORF241**   −        3       18777   18700   78 \| 25

###### 

Identified potential drug leads against protease and replication polymerase novel corona virus targets.

  S. No   Drug name             Target Viral Protein       ΔG (Free Energy of Binding) kcal/mol   Inhibition Constant Ki
  ------- --------------------- -------------------------- -------------------------------------- ------------------------
  1\.     Paritaprevir          Proteases                  −9.32                                  147.06 nM
  2\.     Ergotamine tartrate   Proteases                  −9.23                                  171.72 nM
  3\.     Telaprevir            Proteases                  −8.98                                  260.28 nM
  4\.     Dihydroergotamine     Proteases                  −8.96                                  270.32 nM
  5\.     Simeprevir            Proteases                  −8.61                                  489.77 nM
  6\.     Ergotamine alkaloid   Proteases                  −8.54                                  1.85 uM
  7\.     Telmisartan           Proteases                  −7.36                                  4.03 uM
  8\.     Ritonavir tartrate    Proteases                  −7.30                                  4.48 uM
  9\.     FGI 106               Proteases                  −7.14                                  5.82 uM
  10\.    Corosolic acid        Proteases                  −7.09                                  6.33 uM
  11\.    Chloroquine           Proteases                  −6.96                                  7.94 uM
  12\.    Darunavir             Proteases                  −6.94                                  8.15 uM
  13\.    Nelfinavir            Proteases                  −6.79                                  10.55 uM
  14\.    Glycyrrhizic acid     Proteases                  −6.75                                  11.26 uM
  15\.    Baicalin              Proteases                  −6.58                                  15.00 uM
  16\.    Ritonavir             Proteases                  −6.39                                  20.64 uM
  17\.    quilajja saponin      Proteases                  −6.16                                  30.59 uM
  18\.    Lopinavir             Proteases                  −5.92                                  45.67 uM
  19\.    Amprenavir            Proteases                  −5.82                                  54.06 uM
  20\.    Fosamprenavir         Proteases                  −4.94                                  240.42 uM
  21\.    Quercetin             Proteases                  −4.74                                  338.05 uM
  22\.    Remdesivir            Proteases                  −4.53                                  475.88 uM
  23\.    Pemetrexed            RdRp (viral Replication)   −6.49                                  17.54 uM
  24\.    Raltitrexed           RdRp (viral Replication)   −6.71                                  12.08 uM
  25\.    Sofosbuvir            RdRp (viral Replication)   −5.40                                  30.89 uM

###### 

Identified potential drug leads against human furin proteases for novel corona virus targets.

  S. No.   Drug Name           Target Protein   ΔG (Free Energy of Binding) kcal/mol   Inhibition Constant Ki
  -------- ------------------- ---------------- -------------------------------------- ----------------------------
  1\.      Chloroquine         Furin            −8.61 kcal/mol                         487.42 nM
  2\.      Baicalin            Furin            −7.40 kcal/mol                         3.75 uM
  3\.      Corosolic acid      Furin            −7.67 kcal/mol                         2.41 uM
  4\.      Glycyrrhizic acid   Furin            −5.84 kcal/mol                         52.76 uM (mild inhibitor)
  5\.      Paritaprevir        Furin            −10.02 kcal/mol                        45.27 nM(strong inhibitor)
  6\.      Ritonavir           Furin            −7.91 kcal/mol                         1.58 uM
  7\.      Remdesivir          Furin            −4.81 kcal/mol                         300.08 uM

###### 

Identified potential drug leads against papain like proteases of novel corona virus targets.

  S. No   Drug Name      Target Protein          ΔG (Free Energy of Binding) kcal/mol   Inhibition Constant Ki
  ------- -------------- ----------------------- -------------------------------------- ----------------------------
  1\.     Paritaprevir   papain like proteases   −7.09 kcal/mol                         6.40 uM
  2\.     Lopinavir      papain like proteases   −4.25 kcal/mol                         772.95 uM (weak inhibitor)
  3\.     Ritonavir      papain like proteases   −4.73 kcal/mol                         339.64 uM
  4\.     Chloroquine    papain like proteases   −7.28 kcal/mol                         4.61 uM
  5\.     Remdesivir     papain like proteases   −5.66 kcal/mol                         70.56 uM (weal inhibition)
